Clinical Trials Logo

Macular Disease clinical trials

View clinical trials related to Macular Disease.

Filter by:

NCT ID: NCT05588037 Recruiting - Cataract Clinical Trials

Combined Vitrectomy and Femtosecond Laser-assisted Cataract Surgery

Start date: January 1, 2017
Phase: N/A
Study type: Interventional

Based on the progress of cataract surgery, intraocular lens development, vitreoretinal surgery and anesthesia technology in recent years, the purpose of this study is to develop a new type of more accurate and minimally invasive combined surgery for cataract and fundus diseases, and to evaluate the advantages and value of the surgery as well as related complications, so as to minimize the surgical trauma and obtain faster visual function recovery and better patient comfort. To provide new solutions for the growing demand of eye health care.

NCT ID: NCT05497128 Not yet recruiting - Macular Disease Clinical Trials

Standard Cut Rate 27-Gauge System Versus Ultrahigh-Speed 27-Gauge System in Macular Surgery

Start date: September 2022
Phase: N/A
Study type: Interventional

The purpose of this study is to compare the efficiency and safety of ultrahigh-speed cut rate 27-gauge system (27+®GA HYPERVIT® Vitrectomy Probe (Alcon Laboratories, Fort Worth, TX, USA)) and standard cut rate 27-gauge vitrectomy system (27+®GA Advanced ULTRAVIT® Vitrectomy Probe (Alcon Laboratories, Fort Worth, TX, USA)).

NCT ID: NCT05130385 Recruiting - Glaucoma Clinical Trials

High Resolution Optical Coherence Tomography

Start date: November 30, 2021
Phase:
Study type: Observational

Comparison of high-resolution optical coherence tomography (High-Res-OCT) to conventional imaging modalities for the diagnosis of eye diseases

NCT ID: NCT04607369 Enrolling by invitation - Macular Disease Clinical Trials

Implementation of the NEDS EyeCTester App

Start date: January 9, 2019
Phase:
Study type: Observational

Group 4a and 4b was an FDA trial that showed that patients who have an Amsler grid abnormality on paper, have a similar abnormality on the app. Group 7a and 7b was an FDA trial that showed that normal patients do not have false positives on the Amsler app as well as on the Amsler paper version. Further Vision on the app is slightly better than vision on the standard Sloan near card using a formula (vision is 7/10th of a line better on the app).

NCT ID: NCT03823092 Recruiting - Cataract Clinical Trials

Polarization Perception in Health and Disease. Testing a New Sight Test

TaNSiT
Start date: November 9, 2017
Phase:
Study type: Observational

A study to assess the utility of human polarization pattern perception for the detection, diagnosis and monitoring of eye disease

NCT ID: NCT03376776 Completed - Macular Disease Clinical Trials

Epiretinal Proliferation in Eyes With Full Thickness Macular Hole

Start date: March 2013
Phase: N/A
Study type: Observational

We evaluated preoperative and postoperative optical coherence tomograpghic images in eyes with full thickness macular hole (FTMH) whether the epiretinal proliferation (EP) was detected and detection of EP was correlated to the visual improvement.

NCT ID: NCT03244007 Completed - Macular Disease Clinical Trials

Evaluation of Retinal Microstructure Detected With Intraoperative Optical Coherence Tomography During Vitrectomy

Start date: December 12, 2015
Phase:
Study type: Observational

We evaluate the intraoperative optical coherence tomographic (OCT) images of eyes with idiopathic macular hole (MH) or lamellar macular hole whether the intraoperative OCT findings will affect postoperative visual outcome.

NCT ID: NCT02321267 Recruiting - Macular Disease Clinical Trials

Cohort Study of the Clinical Course of Macular Diseases in Kagawa

Start date: December 2014
Phase: Phase 4
Study type: Interventional

Macular diseases often cases severe visual impairment. Recent clinical introduction of anti-vascular endothelial growth factor agents may change the clinical course of various macular diseases, including age-related macular degeneration (AMD), polypoidal choroidal vasculopathy (PCV), retinal angiomatous proliferation (RAP), central serous chorioretinopathy (CSC), myopic choroidal neovascularization (CNV), retinal vein occlusion (RVO), diabetic macular edema (DME), and so forth. The advance in vitrectomy improve visual outcomes in some maculae diseases, including epiretinal membrane (ERM), macular hole (MH), vitreomacular traction syndrome (VMTS). Patients with such macular diseases are registered and are followed up for 5 years with appropriate treatment for each patient. By the analysis of the correlation between initial examinations and final visual acuity, factors associated with good visual prognosis will be elucidated.

NCT ID: NCT02081339 Recruiting - Macular Disease Clinical Trials

Cohort Study of the Clinical Course of Macular Diseases in Japanese

Start date: March 2014
Phase: N/A
Study type: Observational [Patient Registry]

Recent clinical introduction of anti-vascular endothelial growth factor agents may change the clinical course of macular diseases, including age-related macular degeneration (AMD), polypoidal choroidal vasculopathy (PCV), retinal angiomatous proliferation (RAP), central serous chorioretinopathy (CSC), myopic choroidal neovascularization (CNV), retinal vein occlusion (RVO), diabetic macular edema (DME), and so forth. Patients with such macular diseases are registered and and are followed up for 5 years with appropriate treatment for each patient. By the analysis of the correlation between initial examinations and final visual acuity, factors associated with good visual prognosis will be elucidated.

NCT ID: NCT01994174 Terminated - Macular Disease Clinical Trials

Effect of Vascular Endothelial Growth Factor Blockers on Aqueous Humor Dynamics

Start date: December 20, 2013
Phase:
Study type: Observational [Patient Registry]

The objective of this research is to determine the effects of anti-VEGF drugs (bevacizumab, ranibizumab or aflibercept) on aqueous humor dynamics (AHD) in patients with retinal vascular disease. The underlying hypothesis is that anti-VEGF drugs increase intraocular pressure (IOP) by increasing aqueous inflow, decreasing uveoscleral outflow or both. The specific aim is to evaluate the changes produced in AHD after 1 baseline and a subsequent 1 monthly injection of anti VEGF agents.